Clinical Trial Update: A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial assessing the pharmacokinetics and safety of BCD-263 and nivolumab (Opdivo) as monotherapy in patients with advanced melanoma of the sk…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• BCD-263
• OPDIVO (nivolumab)

Snippet

Sponsor: Biocad | Conditions: Advanced Melanoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING